Lutetium-177 Prostate Specific Membrane Antigen Therapy in a Patient With Double Malignancy and Single Functioning Kidney: A Case Report

Naeem, Zikriya; Zahra, Umal Baneen; Younis, Muhammad Numair; Khan, Irfan Ullah; Shahid, Abia

doi:10.7759/cureus.36938

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first case of PSMA-targeted radioligand therapy for non-prostatic cancer was reported in 2017 (33) but was duplicated in a later publication. These 15 publications described 30 patients (34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48). Four were described twice, and one duplicate was excluded (33).…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

GOLAN,

TURSUNOV,

VOLKOV

2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: The current systematic review aimed to collect and analyze all available published and unpublished cases in which prostate-specific membrane antigen (PSMA)-targeted radioligand therapy ( 177 Lu-PSMA) was used to treat non-prostatic cancer. Materials and Methods: Literature search and evidence acquisition through contacts with organizations that use 177 Lu-PSMA were employed. PubMed/Medline, SCOPUS, and ScienceDirect searches were performed following PRISMA recommendations. The search strategy was to screen all articles describing 177 Lu-PSMA radioligand therapy published to date with the key word " 177 Lu-PSMA". These articles were collected and screened for non-prostatic cancer cases. Quality assessment was performed using the GRADE criteria. Results: A total of 713 articles were screened, and the search revealed 15 eligible records. Forty patients with a mean age of 51.2±18.5 years were treated with 177 Lu-PSMA for non-prostatic cancer. Of them, 30 cases were published, and 10 were found in medical institution records. Cancers of the salivary glands were most often targeted (13/40), followed by various brain cancer types (8/40), and osteosarcoma (6/40). The authors used previously established protocols for castration-resistant prostate cancer with the dose per cycle as 6.0-7.4 GBq and the number of cycles between one and four. Toxicity was estimated as low, and 21 out of 28 patients with reported outcomes survived to the time of the publication. Conclusion: PSMA-targeted radioligand therapy was infrequently used to treat different non-prostatic cancer types in various target organs. These pioneering efforts indicate that 177 Lu-PSMA can be used to treat non-prostatic cancer with PSMA expression. The toxicity of such treatment was low, and the outcome was relatively good.

show abstract

Section: Resultsmentioning

confidence: 99%

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

GOLAN,

TURSUNOV,

VOLKOV

2024

Anticancer Res

View full text Add to dashboard Cite

show abstract

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium

Ramonaheng,

Qebetu,

Ndlovu

et al. 2024

Front. Nucl. Med.

View full text Add to dashboard Cite

Radiopharmaceutical therapy has been widely adopted owing primarily to the development of novel radiopharmaceuticals. To fully utilize the potential of these RPTs in the era of precision medicine, therapy must be optimized to the patient's tumor characteristics. The vastly disparate dosimetry methodologies need to be harmonized as the first step towards this. Multiple factors play a crucial role in the shift from empirical activity administration to patient-specific dosimetry-based administrations from RPT. Factors such as variable responses seen in patients with presumably similar clinical characteristics underscore the need to standardize and validate dosimetry calculations. These efforts combined with ongoing initiatives to streamline the dosimetry process facilitate the implementation of radiomolecular precision oncology. However, various challenges hinder the widespread adoption of personalized dosimetry-based activity administration particularly when compared to the more convenient and resource-efficient approach of empiric activity administration. This review outlines the fundamental principles, procedures, and methodologies related to image activity quantification and dosimetry with a specific focus on 177Lutetium based radiopharmaceuticals.

show abstract

Lutetium-177 Prostate Specific Membrane Antigen Therapy in a Patient With Double Malignancy and Single Functioning Kidney: A Case Report

Cited by 2 publications

References 13 publications

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium

Contact Info

Product

Resources

About

Lutetium-177 Prostate Specific Membrane Antigen Therapy in a Patient With Double Malignancy and Single Functioning Kidney: A Case Report

Cited by 2 publications

References 13 publications

Systematic Review of the First 40 Cases of177Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

Systematic Review of the First 40 Cases of177Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium

Contact Info

Product

Resources

About

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer

Systematic Review of the First 40 Cases of¹⁷⁷Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer